Herein we demonstrate that isomaltosoide, an iron formulation used for correction of iron deficiency in humans, negatively impacts on the efficacy of cancer immunotherapy and combined IL-2/doxorubicin chemo-immunotherapy in a murine E0771 mammary carcinoma model. This evidence concerns the gene IL2 and cancer.